
#### Plastic vs. Glass: DMEK Endothelial Cell Loss Due to Graft Injector Method

November 13, 2015







#### FINANCIAL DISCLOSURE


**Nothing to disclose** 





#### Tissue Utilization Trends

**Figure 2: Domestic DSEK Trends** 



**Figure 3: Domestic DMEK Trends** 




Table 4: Domestic Endothelial Keratoplasty Numbers Annual Comparison 2012 - 2014


Domestic Surgery Use	2014	2013	2012
Total Endothelial Keratoplasty Procedures	25,965	24,987	23,049
DSEK, DSAEK, DLEK Procedures	23,100	23,465	22,301
DMEK or DMAEK Procedures	2,865	1,522	748





#### Portland Eye Bank Utililization Trends Right Now

Lions VisionGift, Oregon





# Background

- Variety of Surgical and Graft preparation techniques -No Consensus
  - Liarakos VS, Dapena I, Ham L, et al.. JAMA Ophthalmol 2013;131:29-35.
  - Yoeruek E, Bayyoud T, Hofmann J, et al. Cornea 2013;32:370-3.



Dapena I, Moutsouris K, Droutsas K, et al. Arch Ophthalmol 2011; 129:88 - 94 Yoeruek E. Bayyoud T. Hofmann J. Bartz-Schmidt KU., Cornea 2013:32(3):370-3. Terry MA, Straiko MD, Veldman PB, et al. Cornea 2015.



- Modified IOL cartridges
  - Kruse FE, Laaser K, Cursiefen C, et al. Cornea 2011; 30:580 587.
  - Price MO, Price FW Jr. Curr Opin Ophthalmol 2013; 24:329–335.
  - Muraine M, Gueudry J, He Z, et al. Am J Ophthalmol 2013; 156:851 859.
  - Güell JL, Morral M, Gris O, et al. Cornea 2013; 32:1521 1526.
  - Kim EG, Todd L, Zhu A, Jun AS. Cornea. 2014 Jun;33(6):649-52.



- Aspiration
- "Pick up and put in" with forceps
- Dimensions of injectors differ greatly—
  - Radius of ejection orifice may not matter Yoeruek E, Bartz-Schmidt KU, Hofmann J. Acta Ophthalmol. 2015 Jul 8.
- Ejection infusion pressures may differ significantly



















# Patterns of Endothelial Cell Loss in DMEK tissues are Complex












# Complex Death Patterns and More Endothelial cell loss than anticipated





	%ECL as analyzed by Fiji			%ECL as analyzed by Adobe				
Sample	Reader 1	Reader 2	Reader 3	Average	Reader 1	Reader 2	Reader 3	Average
1	17.77	15.39	17.32	16.83	14.59	12.7	17.58	14.96
2	23.52	23.78	20.3	22.53	17.19	17.51	19.87	18.19
3	21.06	23.72	22.04	22.27	20.48	24.2	22.42	22.37
4	14.92	13.06	13.28	13.75	10.62	10.7	11.38	10.9
5	26.12	25.59	23.31	25.01	15.41	16.64	15.84	15.96
6	36.58	33.98	31.86	34.14	30.3	29.47	31	30.26
7	26.66	30.58	25.4	27.55	23.82	25.89	27.5	25.74
8	18.9	18.57	17	10.40	10.58	11.89	10.2	10.01
Average				22.5				18.66

Endothelial Cell Loss determined by 2 different methods

Jardine G, Holiman J, Stoeger C, Chamberlain WD Curr Eye Res 2014



# Graft Manipulation

Jones Tube--Glass



Viscoject (Endoject)--Plastic







### Difference in Injector Parameters

Viscoject (Endoject)--Plastic

Jones Tube--Glass





	Plastic	Glass	
Average volume	0.13±0.004 cm <sup>3</sup>	0.414±0.075 cm <sup>3</sup>	
Average Horizontal opening	1.91±0.04 mm	2.37±0.22 mm	
Average Vertical opening	1.94±0.07 mm	2.40±0.05 mm	
Average orifice area	2.91 mm²	4.45 mm <sup>2</sup>	
	~150% larger area of opening		



# Study Design


- Powered to detect a 10% difference in cell loss
- Confidence level of 90% ( $\alpha$ = 0.05)
- 9 grafts for each injector 18 total (not suitable for transplantation)
- 2 Readers were masked to injector type
  - (no sig difference between 2 reader's results)

	Insertion Method			
	Modified Jones	Viscoject	p-value	
	Tube			
Donor Age (years)	61 ± 3	60 ± 3	0.2	
range	50-74	52-73		
Death-to-Preservation	11.4 ± 8	18.0 ± 10	0.1	
(hours) range	5-23	7-32		
Pre-Peel Cell Count	2484 ± 125	2717 ± 120	0.2	
range	2012-3049	2045-3195		
Post-Peel Cell Count	2407 ± 127	2506 ± 153	0.6	
range	1887-2941	1848-3247		






#### Peeling Damage Patterns




Heavy Damage after complete peel






### Trephination and Touch Damage






# "S" Stamp Damage











< 0.61% (±0.2%) cell death










# Injector Damage





Fine Parallel "scrape" lines

Viscoject 2.2

**Modified Jones Tube** 






# NO sig difference between Glass and Plastic

We may be losing ~30% of cells by eye bank preparation and passage through tube into the eye

5-10% from injector step alone

		Insertion Method			
		Modified Jones	Viscoject	p-value	
		Tube			
Donor Age (yea	ars)	61 ± 3	60 ± 3	0.2	
range		50-74	52-73		
Death-to-Preserv	ation	11.4 ± 8	18.0 ± 10	0.1	
(hours) range	e	5-23	7-32		
Pre-Peel Cell Co	ount	2484 ± 125	2717 ± 120	0.2	
range		2012-3049	2045-3195		
Post-Peel Cell C	ount	2407 ± 127	2506 ± 153	0.6	
range		1887-2941	1848-3247		
%Cell Loss		27% ± 5%	32% ± 8%	0.3	
95% confidence in	terval	24% to 29%	24% to 35%		
range		21% to 35%	21% to 47%		









- Recently commercially available in US
- No 510K approval
- Glass
- Requires smaller incision than other 2 injectors
- Potential advantages
  - smaller incision
  - Greater chamber stability
- Potential disadvantages
  - Cost
  - Damage to graft do to output radius of injector







# DORC Glass injector







	Viscoject	Modified Jones Tube	DORC Glass Injector
Average volume	0.13±0.004 cm <sup>3</sup>	0.414±0.075 cm <sup>3</sup>	0.325±0.075 cm <sup>3</sup>
Average Horizontal opening	1.91±0.04 mm	2.37±0.22 mm	IN: 3.82±0.01 mm OUT: 0.52±0.01 mm
Average Vertical opening	1.94±0.07 mm	2.40±0.05 mm	IN: 3.82±0.01 mm OUT: 0.685 ±0.01 mm
Average orifice area	2.91 mm <sup>2</sup>	4.45 mm <sup>2</sup>	IN: 11.4 mm <sup>2</sup> OUT:1.12 mm <sup>2</sup>
Endothelial cell loss	32%±8%	27%±5%	30.6%±9%



# Study weakness

- Powered to detect 10%, not less
- Tightness of scrolling could not be controlled (no age difference)
- Grafts were not actually injected into anterior chamber (possible difference in fluid dynamics)
- Grafts unfurled on a bed of viscoelastic









#### Conclusions

- No significant Difference in endothelial cell loss between Modified Jones tube (Glass) and Viscoject (Plastic) despite material and dimensional differences
- DORC Glass Injector may perform very similarly
- Parallel scrape marks visible regardless of injector type but reduced in DORC injector
- Near 30% ECD to peel and trephine graft and deliver it to anterior chamber (5-10% from the injector step alone)



#### <u>Acknowledgements</u>

Julie Schallhorn, MD
Adrian Dokey, MD
Jeffrey Holiman, CEBT
Khoa Tran, PhD
Chris Stoeger CEBT

Lions VisionGift, Portland









# Calcein AM Staining

- Cell permeable compound (Invitrogen, Inc.)
- It is hydrolyzed to strongly green fluorescent non-membrane permeable compound by esterases in live cells





- Retained in live cells with intact membrane
- More sensitive than Trypan blue methods due to functional and membrane integrity component of stain